|
Patent landscape, scope, and claims summary: |
Executive summary
United States Patent 10,064,856 claims broad solid oral, immediate-release, dual-matrix compositions combining (i) a first active that treats or prevents a condition and (ii) a second active that prevents or reduces a secondary symptom. The independent claim set as provided is heavily constrained only by: (1) the immediate-release second matrix, (2) a two-matrix architecture, and (3) the class-to-class pairing where the first active belongs to a specified signaling/pharmacologic bucket (serotonin receptor agonist with ergot or triptan, beta blocker, vasoconstrictor, anti-platelet agent, anti-convulsant, or CGRP receptor antagonist). As written, the claim language functions as a platform claim: it can capture a wide range of known actives (often including multiple members of each class) in a single formulation concept, creating substantial claim surface for many combination products that use immediate-release layers or matrices.
United States Patent 10,064,856: What claims cover for solid oral immediate-release dual-matrix combination drugs?
What exactly does US 10,064,856 claim (independent-claim structure)?
Core claim template (as provided in claim 1–7):
A solid oral pharmaceutical composition with:
-
First matrix
- Contains an effective amount of a first pharmaceutically active agent for treating or preventing a condition.
-
Second matrix
- Contains an effective amount of a second pharmaceutically active agent for preventing or reducing a secondary symptom associated with the condition.
- The second matrix is “an immediate release matrix.”
-
Timing and dosage form constraint
- The only explicit release constraint in the provided claim set is on the second matrix (immediate release). The first matrix release profile is not expressly limited in the snippet, which increases coverage latitude (the first matrix could be delayed, extended, or also immediate release depending on the full specification and dependent claims not provided).
-
First-active class constraints (claim-by-claim substitution lists)
- Claim 1: first active is a serotonin receptor agonist comprising an ergot (ergotamine, methysergide, or zonisamide).
- Claim 2: first active is a serotonin receptor agonist comprising a triptan (naratriptan, almotriptan, sumatriptan, zolmitriptan, eletriptan, frovatriptan, or rizatriptan).
- Claim 3: first active is a beta blocker (broad set including metoprolol, propranolol, carvedilol, nebivolol, etc.).
- Claim 4: first active is a vasoconstrictor (isometheptene mucate, caffeine, pseudoephedrine, ergine, methylphenidate, or psilocybin).
- Claim 5: first active is an anti-platelet agent (aspirin/acetylsalicyclic acid, clopidogrel, ticlopidine, cilostazol, and multiple GP IIb/IIIa antagonists including abciximab, eptifibatide, tirofiban, defibrotide, dipyridamole; with typos “defibrotide” and “acetylsalycyclic acid” in the provided text).
- Claim 6: first active is an anti-convulsant (very large list including topiramate, valproate-related items are not explicitly listed, zonisamide, lamotrigine, gabapentin, pregabalin, levetiracetam, brivaracetam, etc.).
- Claim 7: first active is a CGRP receptor antagonist (MK-0974, CGRP8-37, BIBN 4096 BS, quinine, nitrobenzamide, 4-oxobutanamide, cyclopropane derivative, or benzimidazolinyl piperidine).
Why this claim is a “platform” risk for product developers
The key monetizable IP idea is not only “drug A + drug B.” It is:
- Two-matrix architecture, with
- immediate release assigned to the second matrix, and
- first active restricted only to a listed set of drug types.
That combination of features tends to:
- capture many pairing combinations between the platform’s “first-active class” and any appropriately defined “second-active” that fits “secondary symptom” language; and
- raise design-around difficulty if competitors cannot clearly change the architecture (e.g., single matrix tablet/capsule, different release partitioning, or non-overlapping class selection).
How many drugs are enumerated as first-actives in US 10,064,856 and what categories are covered?
Enumerated first-active buckets (as provided)
| Claim |
First-active category |
Enumerated members in provided text (examples) |
Breadth implication |
| 1 |
Serotonin receptor agonist (ergot) |
Ergotamine, methysergide, zonisamide (note: zonisamide is more commonly an anticonvulsant; here it appears in the “ergot” list as provided) |
Targets migraine/related serotonergic conditions but claim reads on “effective amount … for treating or preventing a condition.” |
| 2 |
Serotonin receptor agonist (triptans) |
Naratriptan, almotriptan, sumatriptan, zolmitriptan, eletriptan, frovatriptan, rizatriptan |
Broad capture of triptan family in same formulation architecture. |
| 3 |
Beta blockers |
Acebutolol through timolol, plus multiple stereoisomeric and mixed alpha/beta agents (e.g., carvedilol, labetalol) |
Coverage can reach cardiovascular indications and off-label symptom framing. |
| 4 |
Vasoconstrictors |
Isometheptene mucate, caffeine, pseudoephedrine, ergine, methylphenidate, psilocybin |
Very wide and includes psychoactive/central stimulants if a court treats “vasoconstrictor” label strictly to what the specification says. |
| 5 |
Anti-platelet agents |
Acetylsalicyclic acid (aspirin), clopidogrel, ticlopidine, cilostazol, abciximab, eptifibatide, tirofiban, dipyridamole, etc. |
Captures both small molecules and biologic-like agents in a “solid oral composition” claim, which may create enforcement and enablement disputes depending on the full disclosure. |
| 6 |
Anti-convulsants |
Massive list including topiramate, zonisamide, lamotrigine, gabapentin, pregabalin, carbamazepine, oxcarbazepine, levetiracetam, brivaracetam, lacosamide is not listed, etc. |
Very broad and overlaps many branded and generic neurological medicines. |
| 7 |
CGRP receptor antagonists |
MK-0974, CGRP8-37, BIBN 4096 BS, quinine, nitrobenzamide, 4-oxobutanamide, cyclopropane derivative, benzimidazolinyl piperidine |
Enumerates both peptides and small-molecule/derivative frameworks; can overlap migraine and other CGRP-pathway indications. |
Critical observation: With only the first matrix class constrained, the “second matrix” can be almost any active that is argued to reduce a “secondary symptom” associated with the condition. The breadth of “secondary symptom” is where enforcement leverage often sits in these formulation patents.
What immediate-release vs non-immediate-release elements matter for infringement analysis?
Is “immediate release matrix” limiting?
As provided, the second matrix is explicitly “an immediate release matrix.” That is the strongest release-limiting term in the claim snippet.
Implication for infringement:
- If an accused product uses two physically distinct matrices and the second matrix releases its second active immediately (as tested under relevant USP dissolution paradigms or FDA-validated methods), infringement is more likely.
- If the accused product instead:
- uses a single matrix, or
- uses immediate release for the first active rather than the second, or
- uses delayed/controlled release for the “second” active,
then the claim element may not be met.
What about the first matrix release profile?
The provided claims do not specify that the first matrix is immediate release or delayed release. That can broaden coverage:
- a court could read the first matrix as any release profile that still produces the overall composition definition; and
- design-arounds should focus on eliminating two-matrix separation or shifting the immediate-release property away from the “second matrix.”
Which courts and legal standards typically decide how broad “secondary symptom” and “matrix” terms are?
This is a formulation patent, so claim construction usually turns on:
- intrinsic evidence (specification and prosecution history),
- ordinary meaning of “matrix,” and
- whether “secondary symptom” is interpreted as a structural limitation (what is the symptom) or as a functional limitation (what effect does the second agent provide).
High-level enforcement posture implied by the claim drafting:
- The claims are written to be product-agnostic beyond the two-matrix structure and class constraints on the first active.
- Enforcement often hinges on whether the “second agent” can be characterized as reducing a secondary symptom of the treated condition and whether the release behavior maps to “immediate release matrix.”
What generic entry risks exist for US 10,064,856 platform compositions?
Does the claim read on generics?
If a generic manufacturer copies:
- the same two-matrix architecture, with
- the same first-active from the enumerated set, and
- the same second-active framed as preventing/reducing a secondary symptom,
then it can fall within the claim scope even if it markets a different indication.
Where generics can design around fastest (claim-element targeted)
-
Remove the “two matrices” architecture
- Use a single matrix formulation for both drugs.
-
Change which matrix is immediate release
- Make the second matrix not immediate release (or move immediate release to the first matrix), if the product is operationally and clinically viable.
-
Change the first-active class membership
- Replace the first active with a non-enumerated agent outside the claim’s category lists, if the full claim requires literal match rather than equivalence.
-
Reframe “secondary symptom” beyond credible labeling/therapeutic mechanism
- A narrow interpretation of “secondary symptom associated with the condition” can help if the second agent is not recognized as addressing that symptom in the specification or regulatory record.
What formulations are protected by US 10,064,856 (dosage forms, layering, and composite tablets)?
Does the claim require specific manufacturing methods?
The provided claims describe:
- “first matrix” and “second matrix,” and
- a release partition for the second matrix.
They do not, as provided, require:
- hot-melt extrusion,
- coacervation,
- granulation method,
- specific layering counts,
- or any polymer identity.
That absence usually increases claim coverage to multiple manufacturing platforms capable of yielding two functional matrices.
Practical interpretation for product developers
A likely protected configuration (based on typical “matrix” language in oral formulation patents) is a tablet/capsule where:
- one active is incorporated in one matrix domain, and
- the other active is in a different domain with dissolution properties consistent with “immediate release.”
How strong is the patent estate for US 10,064,856: what matters beyond claim 1–7?
A critical issue is that the provided material includes only selected claim text (1–7), not:
- the full claim set,
- dependent claim narrower embodiments,
- the specification’s enabling details, or
- prosecution history.
Enforcement strength usually depends on:
- how many additional dependent claims narrow architecture or specify polymer/dissolution characteristics,
- whether the specification describes preferred embodiments that match commercial products,
- whether certain enumerated “first actives” are supported in a way that avoids enablement or written description challenges.
With only the provided claim text, the most defensible conclusion is structural: the claim scope is broad by architecture and class-list enumeration.
Patent expiration and exclusivity timelines for US 10,064,856
No reliable expiration/exclusivity computation is possible from the provided prompt because the key inputs are missing:
- filing date,
- earliest priority date,
- patent term adjustment (PTA),
- patent term extension (PTE),
- and whether any regulatory exclusivity (e.g., NCE/505(b)(2) exclusivity) is relevant to this patent’s enforcement strategy.
No accurate timeline can be stated without those facts.
Orange Book status, FDA approval linkage, and Paragraph IV risk
No Orange Book mapping can be produced from the provided prompt.
A correct Orange Book analysis requires:
- the Orange Book-listed products,
- listed drug names,
- active ingredients and dosage forms matched to the claim’s first/second actives,
- and whether US 10,064,856 is listed with those products.
Without those items, an actionable status table cannot be built.
Key Takeaways
- US 10,064,856 claim set (as provided) is a two-matrix, solid oral, immediate-release-on-second-matrix formulation concept that can capture many combination products where the first active is limited to an enumerated set of drug classes (ergot/triptan serotonin agonists, beta blockers, vasoconstrictors, anti-platelet agents, anti-convulsants, CGRP receptor antagonists).
- The main scope lever is the requirement that the second matrix is immediate release; the first matrix release profile is not constrained in the provided language, increasing coverage breadth.
- The main enforcement lever is likely functional: whether the second agent can credibly be positioned as preventing/reducing a secondary symptom associated with the condition.
- Design-around options implied by the claim language target: (i) removal of two-matrix structure, (ii) shifting immediate release away from the “second matrix,” and (iii) replacing the “first-active class” member outside the enumerated buckets.
FAQs
- What does “immediate release matrix” typically mean in formulation patents and how is it tested?
- Do patents like US 10,064,856 cover single-tablet fixed-dose combinations or only layered systems?
- How do courts construe “secondary symptom associated with the condition” for combination product infringement?
- What design-around strategy is strongest against two-matrix immediate-release claims: matrix architecture or release timing?
- Can formulation patents with enumerated drug lists still be avoided by using non-enumerated analogs in the same class?
References
No sources were provided or cited in the prompt, and no bibliographic data (title, inventors, priority, prosecution, Orange Book listings, or FDA approvals) for US 10,064,856 were included.
More… ↓
⤷ Start Trial
|
